A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis

BMC Cancer

Chih-Ming Lu⁵  Jen-Jie Lin³  Han-Hsiang Huang²  Ying-Chin Ko¹  Jue-Liang Hsu⁴  Jiing-Chuan Chen⁶  Zhong-Hao Din⁷  Yu-Jen Wu² 

[1] Institute of Medicine, China Medical University, Taichung, Taiwan

[2] Department of Beauty Science, Meiho University, Pingtung, Taiwan

[3] Graduate Institute of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, Taiwan

[4] Graduate Institute of Biotechnology, National Pingtung University of Science and Technology, Pingtung, Taiwan

[5] Department of Urology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan

[6] Department of Food Science and Nutrition, Meiho University, Pingtung, Taiwan

[7] Graduate Institute of Applied Healthy and Biotechnology, Meiho University, Pingtung, Taiwan

关键词: Zn-alpha-2-glycoprotein;    Calreticulin;    Annexin A3;    Annexin A2;    Urine;    Proteomic;    Upper tract urothelial carcinoma;   

Others  :  858795
DOI  :  10.1186/1471-2407-14-363

 received in 2013-12-02, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

Upper tract urothelial carcinoma (UTUC) is a tumor with sizable metastases and local recurrence. It has a worse prognosis than bladder cancer. This study was designed to investigate the urinary potential tumor markers of UTUC.

Methods

Between January 2008 and January 2009, urine was sampled from 13 patients with UTUC and 20 healthy adults. The current study identified biomarkers for UTUC using non-fixed volume stepwise weak anion exchange chromatography for fractionation of urine protein prior to two-dimensional gel electrophoresis.

Results

Fifty five differential proteins have been determined by comparing with the 2-DE maps of the urine of UTUC patients and those of healthy people. Western blotting analysis and immunohistochemistry of tumor tissues and normal tissues from patients with UTUC were carried out to further verify five possible UTUC biomarkers, including zinc-alpha-2-glycoprotein, calreticulin, annexin A2, annexin A3 and haptoglobin. The data of western blot and immunohistochemical analysis are consistent with the 2-DE data. Combined the experimental data in the urine and in tumor tissues collected from patients with UTUC, the crucial over-expressed proteins are calreticulin, annexin A2, and annexin A3.

Conclusions

Calreticulin, annexin A2, and annexin A3 are very likely a panel of biomarkers with potential value for UTUC diagnosis.

【 授权许可】

   
2014 Lu et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH: The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol 2009, 182:451-458.
• [2]Oldbring J, Glifberg I, Mikulowski P, Hellsten S: Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. J Urol 1989, 141:1311-1313.
• [3]Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 2006, 67:518-523.
• [4]Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol 2005, 174:2120-2123.
• [5]Marshall T, Williams KM: Clinical analysis of human urinary proteins using high resolution electrophoretic methods. Electrophoresis 1998, 19:1752-1770.
• [6]Lu CM, Wu YJ, Chen CC, Hsu JL, Chen JC, Chen JY, Huang CH, Ko YC: Identification of low-abundance proteins via fractionation of the urine proteome with weak anion exchange chromatography. Proteome Sci 2011, 9:17. BioMed Central Full Text
• [7]Kiernan U, Tubbs K, Nedelkov D, Niederkofler E, McConnell E, Nelson R: Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res 2003, 2:191-197.
• [8]Liu CI, Wang YL, Lin JJ, Su JH, Chiu CC, Chen JC, Chen YF, Wu YJ: Proteomic profiling of the 11-dehydrosinulariolide-treated oral carcinoma cells Ca9-22: effects on the cell apoptosis through mitochondrial-related and ER stress pathway. J Proteomics 2012, 75:5578-5589.
• [9]Li HH, Su JH, Chiu CC, Lin JJ, Yang ZY, Hwang WI, Chen YK, Lo YH, Wu YJ: Proteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-relate pathway and activation of caspase cascade. Mar Drugs 2013, 11:2625-2642.
• [10]Rydén M, Agustsson T, Andersson J, Bolinder J, Toft E, Arner P: Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states. J Intern Med 2012, 271:414-420.
• [11]Hisaoka M, Matsuyama A, Nakamoto M: Aberrant calreticulin expression is involved in the dedifferentiation of dedifferentiated liposarcoma. Am J Pathol 2012, 180:2076-2083.
• [12]Zhang X, Liu S, Guo C, Zong J, Sun MZ: The association of annexin A2 and cancers. Clin Transl Oncol 2012, 14:634-640.
• [13]Wu N, Liu S, Guo C, Hou Z, Sun MZ: The role of annexin A3 playing in cancers. Clin Transl Oncol 2012. pub ahead of print
• [14]Carlsson MC, Cederfur C, Schaar V, Balog CI, Lepur A, Touret F, Salomonsson E, Deelder AM, Fernö M, Olsson H, Wuhrer M, Leffler H: Calectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One 2011, 6:e26560.
• [15]Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, Michalak M, Dhir R, Wang Z: Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol 2009, 175:882-890.
• [16]Chignard N, Shang S, Wang H, Marrero J, Brechot C, Hanash S, Beretta L: Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: detection of generated fragments in patient sera. Gastroenterology 2006, 130:2010-2022.
• [17]Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol 2010, 4:65-89.
• [18]Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T: Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004, 95:955-961.
• [19]Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T: Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004, 50:857-866.
• [20]Kageyama S, Isono T, Matsuda S, Ushio Y, Satomura S, Terai A, Arai Y, Kawakita M, Okada K, Yoshiki T: Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int J Urol 2009, 16:481-486.
• [21]Ji NY, Park MY, Kang YH, Lee CI, Kim DG, Yeom YI, Jang YJ, Myung PK, Kim JW, Lee HG, Kim JW, Lee K, Song EY: Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med 2009, 24:765-771.
• [22]Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, Jiang JL, Zhang SH, Chen ZN: Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci 2010, 101:387-395.
• [23]Zhong LP, Wei KJ, Yang X, Zhang L, Zhou XJ, Pan HY, Li J, Chen WT, Zhang ZY: Increased expression of Annexin A2 in oral squamous cell carcinoma. Arch Oral Biol 2009, 54:17-25.
• [24]Gerke V, Creutz CE, Moss SE: Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005, 6:449-461.
• [25]Park JE, Lee DH, Lee JA, Park SG, Kim NS, Park BC, Cho S: Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 2005, 337:1283-1287.
• [26]Minelli A, Ronquist G, Carlsson L, Mearini E, Nilsson O, Larsson A: Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res 2005, 25:4399-4402.
• [27]Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A, Schrattenholz A: Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol 2009, 181:343-353.
• [28]Madoz-Gúrpide J, López-Serra P, Martínez-Torrecuadrada JL, Sánchez L, Lombardía L, Casal JI: Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics 2006, 5:1471-1483.
• [29]Yin J, Yan X, Yao X, Zhang Y, Shan Y, Mao N, Yang Y, Pan L: Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med 2012, 16:337-348.
• [30]Roobol MJ, Haese A, Bjartell A: Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 2011, 1:85-89.
• [31]Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J: Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:12-19.
• [32]Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 2004, 101:2500-2505.
• [33]Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Ergun S: Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5:4296-4304.
• [34]Hale L, Price D, Sanchez L, Demark-Wahnefried W, Madden J: Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001, 7:846-853.
• [35]Skipworth R, Stewart G, Bhana M, Christie J, Sturgeon C, Guttridge D, Cronshaw A, Fearon K, Ross J: Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. Int J Oncol 2010, 36:973-982.
• [36]Carter K, Worwood M: Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 2007, 29:92-110.
• [37]Awadallah SM, Atoum MF: Haptoglobin polymorphism in breast cancer patients form Jordan. Clin Chim Acta 2004, 341:17-21.
• [38]Deng R, Lu Z, Chen Y, Zhou L, Lu X: Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 2007, 34:310-317.